Jiang Yi

Jiang Yi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ZLZhifen Liu
Zhifen Liu
DQDan Qiao
Dan Qiao
YXYifan Xu
Yifan Xu
WZWentao Zhao
Wentao Zhao
YYYang Yang
Yang Yang
YXYong Xu
Yong Xu
Background: The prevalence of depressive and anxiety symptoms in patients with COVID-19 is higher than usual. Previous studies have shown that there are drug-to-drug interactions between antiretroviral drugs and antidepressants. Therefore, an effective and safe treatment method was needed. Cognitive behavioral therapy (CBT) is the first-line psychological therapy in clinical treatment. Computerized CBT (cCBT) was proven to be an effective alternative to CBT and does not require face-to-face therapy between a therapist and the patient, which suited the COVID-19 pandemic response. Objective: This study aims to evaluate the efficacy of the cCBT program we developed in improving depressive and anxiety symptoms among patients with COVID-19. Methods: We customized a cCBT program focused on improving depressive and anxiety symptoms among patients with COVID-19, and then, we assessed its effectiveness. Screening was based on symptoms of depression or anxiety for patients who scored ≥7 on the Hamilton Depression Rating Scale (HAMD17) or the Hamilton Anxiety Scale (HAMA). A total of 252 patients with COVID-19 at five sites were randomized into two groups: cCBT + treatment as usual (TAU; n=126) and TAU without cCBT (n=126). The cCBT + TAU group received the cCBT intervention program for 1 week. The primary efficacy measures were the HAMD17 and HAMA scores. The secondary outcome measures were the Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS), and Athens Insomnia Scale (AIS). Assessments were carried out pre- and postintervention. The patients’ symptoms of anxiety and depression in one of the centers were assessed again within 1 month after the postintervention assessment. Results: The cCBT + TAU group displayed a significantly decreased score on the HAMD17, HAMA, SDS, SAS, and AIS after the intervention compared to the TAU group (all P<.001). A mixed-effects repeated measures model revealed significant improvement in symptoms of depression (HAMD17 and SDS scores, both P<.001), anxiety (HAMA and SAS scores, both P<.001), and insomnia (AIS score, P=.002) during the postintervention and follow-up periods in the cCBT + TAU group. Additionally, the improvement of insomnia among females (P=.14) and those with middle school education (P=.48) in the cCBT + TAU group showed no significant differences when compared to the TAU group. Conclusions: The findings of this study suggest that the cCBT program we developed was an effective nonpharmacological treatment for symptoms of anxiety, depression, and insomnia among patients with COVID-19. Further research is warranted to investigate the long-term effects of cCBT for symptoms of anxiety, depression, and insomnia in patients with COVID-19. Trial Registration: Chinese Clinical Trial Registry ChiCTR2000030084; http://www.chictr.org.cn/showprojen.aspx?proj=49952

31 May 2023 in Journal of Asthma
Verified
Journal Article
Closed access
JYJiang Yi
Jiang Yi
QYQianru Yue
Qianru Yue
RARuoli An
Ruoli An
ZTZenghua Tie
Zenghua Tie
YLYing Liu
Ying Liu
XKXiaomei Kong
Xiaomei Kong
Asthma is a common chronic respiratory disease that seriously affects the health of adults and children. The risk factors for asthma are constantly changing; thus, it is necessary to study the prevalence of asthma and risk factors in different populations. Currently, there have been no epidemiological studies on the prevalence and risk factors of asthma in people over 14 years in mainland China. Therefore, we performed a meta-analysis of the prevalence and risk factors for asthma in mainland China. A literature search was conducted for studies on the epidemiology of asthma in China between 2000 and 2020 using English and Chinese databases. Prevalence and epidemiological information on asthma in people aged >14 years were extracted. Meta-analysis was performed using a random-effects model (If I2 > 50%) with 95% confidence intervals for forest plots. Nineteen studies (including data from 345,950 samples) met our evaluation criteria. The overall prevalence of asthma in Chinese adults is 2%, without differences between Northern and Southern China. The prevalence increased after 2010 compared with that before 2010. The prevalence of asthma also increased with age, with people aged 55–64 years being the most affected. The prevalence of asthma was independent of sex and residence area. In conclusion, the prevalence of asthma among adolescents (age > 14 years) and adult population in China has increased since 2010. Further studies are necessary to monitor the prevalence of asthma in mainland China. The elderly population also has a high prevalence of asthma, which should be focused on more in the future.

3 May 2021 in Allergy, Asthma & Clinical Immunology
Verified
Journal Article
Open access
PDF file
JYJiang Yi
Jiang Yi
RARuoli An
Ruoli An
LCLi Cheng
Li Cheng
QYQianru Yue
Qianru Yue
HZHanwei Zhang
Hanwei Zhang
YGYufeng Guo
Yufeng Guo
Background: Investigating the endotypes of the different asthma phenotypes would help disease monitoring, prognosis determination, and improving asthma management standardization. This study aimed to classify asthma into four endotypes according to the allergic and eosinophilic characteristics and explore the phenotypes (clinical characteristics, pulmonary functions, and fractional expired nitric oxide (FeNO)) of each endotype.Methods: This retrospective study included non-acute asthma patients treated at the First Hospital of Shanxi Medical University (05/2016–01/2018). The patients were classified into the eosinophilic allergic, eosinophilic non-allergic, non-eosinophilic allergic, and non-eosinophilic non-allergic asthma endotypes. Serum sIgE, lung function, FeNO, and induced sputum cytology were tested and compared among groups.Results: Of the 171 included patients, 22 had eosinophilic allergic asthma, 17 had eosinophilic non-allergic asthma, 66 had non-eosinophilic allergic asthma, and 66 had non-eosinophilic non-allergic asthma. Lung function measurements (FEV1%, FEF25%, FEF50%, FEF75%, and FEF25–75%) showed that airway dysfunction was worse in eosinophilic non-allergic asthma than in the other three endotypes (all P < 0.001). In allergic asthma patients, eosinophilic asthma had worse airway dysfunction than non-eosinophilic asthma (all P < 0.05). Similar results were found in non-allergic asthma (all P < 0.01). The FeNO levels in eosinophilic allergic asthma were higher than in eosinophilic non-allergic and non-eosinophilic non-allergic asthma (both P = 0.001).Conclusions: FeNO can objectively reflect eosinophilic airway inflammation in asthma. Endotypic classification of asthma patients regarding the allergic and eosinophilic characteristics is conducive to the effective management of patients with asthma.

1 January 2024 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
CZChenwei Zhang
Chenwei Zhang
LYLu Yu
Lu Yu
TXTao Xiong
Tao Xiong
YZYukai Zhang
Yukai Zhang
JLJuan Liu
Juan Liu
JYJiang Yi
Jiang Yi
Background: Chronic Obstructive Pulmonary Disease (COPD), the most prevalent chronic respiratory condition, significantly impairs patients’ quality of life. The pivotal element in disease management lies in prevention, underscoring the paramount importance of employing a scientific approach to investigate early prevention strategies for COPD. Methods: This study delved into the causal link between 28 dietary intakes and COPD employing two-sample Mendelian randomization. We primarily utilized the Inverse Variance Weighted (IVW) method as the main outcome, complemented by Weighted Median (WM), MR-Egger method, along with several sensitivity analysis techniques, all accompanied by visual representations. Results: We identified higher odds of COPD following exposure to green beans (OR=1.381, 95% CI=1.119– 1.704, P=0.003) and pork intake (OR=2.657, 95% CI=1.203– 5.868, P=0.016). In contrast, the odds of developing COPD were lower following exposure to dried fruit (OR=0.481, 95% CI=0.283– 0.819, P=0.007), cereal (OR=0.560, 95% CI=0.356– 0.880, P=0.012), and whole egg consumption (OR=0.700, 95% CI=0.504– 0.972, P=0.033). Conclusion: In light of our study’s findings, we anticipate that strategically modifying dietary choices may offer an avenue for early COPD prevention in the future.

1 January 2021 in JMIR Preprints
Verified
Preprint
Open access
ZLZhifen Liu
Zhifen Liu
DQDan Qiao
Dan Qiao
YXYifan Xu
Yifan Xu
WZWentao Zhao
Wentao Zhao
YYYang Yang
Yang Yang
YXYong Xu
Yong Xu
BACKGROUND The prevalence of depressive and anxiety symptoms in patients with COVID-19 is higher than usual. Previous studies have shown that there are drug-to-drug interactions between antiretroviral drugs and antidepressants. Therefore, an effective and safe treatment method was needed. Cognitive behavioral therapy (CBT) is the first-line psychological therapy in clinical treatment. Computerized CBT (cCBT) was proven to be an effective alternative to CBT and does not require face-to-face therapy between a therapist and the patient, which suited the COVID-19 pandemic response. OBJECTIVE This study aims to evaluate the efficacy of the cCBT program we developed in improving depressive and anxiety symptoms among patients with COVID-19. METHODS We customized a cCBT program focused on improving depressive and anxiety symptoms among patients with COVID-19, and then, we assessed its effectiveness. Screening was based on symptoms of depression or anxiety for patients who scored ≥7 on the Hamilton Depression Rating Scale (HAMD17) or the Hamilton Anxiety Scale (HAMA). A total of 252 patients with COVID-19 at five sites were randomized into two groups: cCBT + treatment as usual (TAU; n=126) and TAU without cCBT (n=126). The cCBT + TAU group received the cCBT intervention program for 1 week. The primary efficacy measures were the HAMD17 and HAMA scores. The secondary outcome measures were the Self-Rating Depression Scale (SDS), Self-Rating Anxiety Scale (SAS), and Athens Insomnia Scale (AIS). Assessments were carried out pre- and postintervention. The patients’ symptoms of anxiety and depression in one of the centers were assessed again within 1 month after the postintervention assessment. RESULTS The cCBT + TAU group displayed a significantly decreased score on the HAMD17, HAMA, SDS, SAS, and AIS after the intervention compared to the TAU group (all P<.001). A mixed-effects repeated measures model revealed significant improvement in symptoms of depression (HAMD17 and SDS scores, both P<.001), anxiety (HAMA and SAS scores, both P<.001), and insomnia (AIS score, P=.002) during the postintervention and follow-up periods in the cCBT + TAU group. Additionally, the improvement of insomnia among females (P=.14) and those with middle school education (P=.48) in the cCBT + TAU group showed no significant differences when compared to the TAU group. CONCLUSIONS The findings of this study suggest that the cCBT program we developed was an effective nonpharmacological treatment for symptoms of anxiety, depression, and insomnia among patients with COVID-19. Further research is warranted to investigate the long-term effects of cCBT for symptoms of anxiety, depression, and insomnia in patients with COVID-19. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2000030084; http://www.chictr.org.cn/showprojen.aspx?proj=49952

5 September 2026
Verified
Conference Paper
Closed access
JYJiang Yi
Jiang Yi
SCShu Cui
Shu Cui

Methods: Sputum from 72 treatment-naïve asthma patients (phenotyped as eosinophilic, neutrophilic, mixed granulocytic, paucigranulocytic) and 30 healthy controls was analyzed using 16S rRNA sequencing and untargeted metabolomics (UHPLC-MS/MS). Analyses included microbial diversity, differential taxa/metabolites, and microbiome-metabolome correlations. Diagnostic potential was assessed via Random Forest and ROC analysis.

方法:使用16 S rRNA测序和非靶向代谢组学(UHPLC-MS/MS)分析了72例未经治疗的哮喘患者(表型为嗜酸性粒细胞、嗜中性粒细胞、混合粒细胞、少粒细胞)和30例健康对照的痰液。分析包括微生物多样性,差异类群/代谢物,和微生物组代谢组的相关性。通过随机森林和ROC分析评估诊断潜力。

Results: Beta-diversity differed between asthma and controls (PERMANOVA p=0.003). Asthmatics showed depletion of Bifidobacterium and enrichment of Capnocytophaga, Neisseria, and Haemophilus. Bifidobacterium demonstrated high diagnostic accuracy (AUC=0.88). Phenotype-specific beta-diversity differences were observed (R²=0.037, p=0.043), identifying nine discriminatory genera. Akkermansia correlated positively with FEV1%pred (r=0.32, p=0.008). Metabolomics identified 489 differential metabolites (56.85% lipids), with efferocytosis pathway enrichment and upregulation of sphingosine-1-phosphate (S1P) and lysophosphatidylcholine (LysoPC). Bifidobacterium depletion correlated with elevated S1P (r=-0.41, p<0.001).

结果:哮喘和对照组之间的β多样性不同(PERMANOVA p=0.003)。哮喘患者双歧杆菌减少,二氧化碳噬纤维菌、奈瑟氏菌和嗜血杆菌增多。双歧杆菌表现出较高的诊断准确性(AUC=0.88)。观察到表型特异性β多样性差异(R²=0.037,p=0.043),确定了9个歧视性属。Akkermansia与FEV1%pred呈正相关(r=0.32,p=0.008)。代谢组学鉴定了489种差异代谢物(56.85%脂质),具有胞浆细胞增多途径富集和1-磷酸鞘氨醇(S1 P)和溶血磷脂酰胆碱(LysoPC)上调。双歧杆菌耗竭与S1 P升高相关(r=-0.41,p 0.001)。

Conclusion: This integrated multi-omics study reveals distinct microbiome-metabolome signatures across asthma phenotypes, linking microbial dysbiosis to pro-inflammatory lipid accumulation and lung function. Findings offer potential biomarkers for phenotype-specific diagnosis and targeted interventions.

结论:这项综合性多组学研究揭示了哮喘表型中不同的微生物组-代谢组特征,将微生物生态失调与促炎脂质积累和肺功能联系起来。这些发现为表型特异性诊断和靶向干预提供了潜在的生物标志物。